Trial | NCT00193531  Report issue

Title

Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma
Phase II Study of Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in the Treatment of High Grade Neuroendocrine Carcinoma

  • Phase

    Phase 2

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    100
carboplatin and etoposide, followed by maintenance therapy with weekly paclitaxel in patients with poorly differentiated neuroendocrine carcinomas. We hope to identify a "standard treatment" for this unusual group of patients who are not usually eligible for clinical trials.
Upon determination of eligibility, patients will be receive:

Paclitaxel + Carboplatin + Etoposide
Study Started
Dec 31
1998
Primary Completion
Jan 31
2007
Study Completion
Jan 31
2007
Last Update
Apr 11
2023

Drug Paclitaxel

Drug Carboplatin

Drug Etoposide

Criteria 

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

Metastatic poorly differentiated neuroendocrine carcinoma
Unknown primary site
Able to perform activities of daily living with minimal assistance
Measurable or evaluable disease
Adequate bone marrow, liver functions and kidney function
No previous treatment with chemotherapy
Understand the nature of this study and give written informed consent.

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

Age < 18 years
Previous malignancy within five years
Women pregnant or lactating
Recent history of cardiovascular disease
Meningeal metastases

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
No Results Posted